AN2 Therapeutics reports Q3 results
Source: SeekingAlpha
2025-11-13 10:20:20 ET
More on AN2 Therapeutics
- Seeking Alpha’s Quant Rating on AN2 Therapeutics
- Historical earnings data for AN2 Therapeutics
- Financial information for AN2 Therapeutics
Read the full article on Seeking Alpha
For further details see:
AN2 Therapeutics reports Q3 results
AN2 Therapeutics Inc.
NASDAQ: ANTX
ANTX Trading
-1.26% G/L:
$1.0663 Last:
2,649 Volume:
$1.07 Open:
ANTX Latest News
February 17, 2026 07:00:00 am
AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference
January 12, 2026 07:00:00 am
AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease
November 12, 2025 04:01:00 pm
AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights
ANTX Stock Data
$30,142,226
20,699,489
1.32%
34
N/A
Biotechnology & Life Sciences
Healthcare
US
Menlo Park
